Clinical trials: Advanced RCC
Colorectal Cancer, Bladder Cancer
Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners
The diagnosis and treatment trajectory of cancer can constitute a traumatic event because these can be perceived as sudden, catastrophic and life threatening.
- Conditions
- Colorectal Cancer, Bladder Cancer, Prostate Cancer, Kidney Cancer
- Trial name
- NeuroPrevPTSD (NCT03652298)
- Testing
- Memory structuring intervention + Vagal breathing, support and attention (usual care)
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Centre Oscar Lambret
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal…
- Trial name
- NCT02231749
- Testing
- Nivolumab, Ipilimumab, Sunitinib
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 1,096 people
- Sponsor
- Bristol-Myers Squibb
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Kidney, Cancer
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
The purpose of this study is to evaluate a therapy combining the established FUNIL regimen with Thalidomide. We want to see how well the therapy works, if it can be easily done, and how well the body handles the treatment.
- Trial name
- NCT00277017
- Testing
- 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Advanced Clear Cell Renal Cell Carcinoma
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with…
- Trial name
- NCT07097935
- Testing
- HS-10516 + Lenvatinib
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Renal Cell Carcinoma (RCC)
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
- Trial name
- NCT04375150
- Testing
- Tyrosine kinase inhibitor (TKI), Immuno-oncology (IO)
- Where
- United States
- Volunteers
- 355 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).
- Trial name
- NCT04033991
- Testing
- Sunitinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 684 people
- Sponsor
- Pfizer
Renal Cell Cancer, Renal Cell Carcinoma
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
- Conditions
- Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney
- Trial name
- NCT05363072
- Where
- Finland
- Volunteers
- 1,112 people
- Sponsor
- Pfizer
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Clear Cell Renal Cell Carcinoma
Investigating Patient Satisfaction With Oral Anti-Cancer Treatment
Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug.
- Trial name
- IPSOC (NCT02247583)
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- KU Leuven
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where…
- Trial name
- NCT05863351
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- 108 sites in United States
- Volunteers
- 472 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00032188
- Testing
- aldesleukin, bryostatin 1, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer).
- Trial name
- NCT01185366
- Testing
- Everolimus, Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Cell Renal Carcinoma
- Trial name
- MACS0460 (NCT00688753)
- Testing
- RAD001
- Where
- 19 sites in Belgium, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Cancer
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients
The rapid development of agents blocking kinases has established the use of molecularly targeted therapy as the preferred treatment approach for patients with metastatic renal cell cancer (RCC).
- Trial name
- NCT02071719
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- M. Labots
Carcinoma, Renal Cell
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
A phase II study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one…
- Trial name
- NCT00338884
- Testing
- Sunitinib malate
- Where
- 15 sites in Argentina, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Pfizer